0001269026 2025-01-01 2025-09-30 0001269026 2025-11-07 0001269026 2025-09-30 0001269026 2024-12-31 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2025-09-30 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2024-12-31 0001269026 SINT:SeriesCConvertiblePreferredStockMember 2025-09-30 0001269026 SINT:SeriesCConvertiblePreferredStockMember 2024-12-31 0001269026 SINT:SeriesDConvertiblePreferredStockMember 2025-09-30 0001269026 SINT:SeriesDConvertiblePreferredStockMember 2024-12-31 0001269026 us-gaap:ProductMember 2025-07-01 2025-09-30 0001269026 us-gaap:ProductMember 2024-07-01 2024-09-30 0001269026 us-gaap:ProductMember 2025-01-01 2025-09-30 0001269026 us-gaap:ProductMember 2024-01-01 2024-09-30 0001269026 SINT:GrantAndContractMember 2025-07-01 2025-09-30 0001269026 SINT:GrantAndContractMember 2024-07-01 2024-09-30 0001269026 SINT:GrantAndContractMember 2025-01-01 2025-09-30 0001269026 SINT:GrantAndContractMember 2024-01-01 2024-09-30 0001269026 2025-07-01 2025-09-30 0001269026 2024-07-01 2024-09-30 0001269026 2024-01-01 2024-09-30 0001269026 us-gaap:PreferredStockMember 2023-12-31 0001269026 us-gaap:CommonStockMember 2023-12-31 0001269026 us-gaap:TreasuryStockCommonMember 2023-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001269026 us-gaap:RetainedEarningsMember 2023-12-31 0001269026 2023-12-31 0001269026 us-gaap:PreferredStockMember 2024-03-31 0001269026 us-gaap:CommonStockMember 2024-03-31 0001269026 us-gaap:TreasuryStockCommonMember 2024-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001269026 us-gaap:RetainedEarningsMember 2024-03-31 0001269026 2024-03-31 0001269026 us-gaap:PreferredStockMember 2024-06-30 0001269026 us-gaap:CommonStockMember 2024-06-30 0001269026 us-gaap:TreasuryStockCommonMember 2024-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001269026 us-gaap:RetainedEarningsMember 2024-06-30 0001269026 2024-06-30 0001269026 us-gaap:PreferredStockMember 2024-12-31 0001269026 us-gaap:CommonStockMember 2024-12-31 0001269026 us-gaap:TreasuryStockCommonMember 2024-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001269026 us-gaap:RetainedEarningsMember 2024-12-31 0001269026 us-gaap:PreferredStockMember 2025-03-31 0001269026 us-gaap:CommonStockMember 2025-03-31 0001269026 us-gaap:TreasuryStockCommonMember 2025-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001269026 us-gaap:RetainedEarningsMember 2025-03-31 0001269026 2025-03-31 0001269026 us-gaap:PreferredStockMember 2025-06-30 0001269026 us-gaap:CommonStockMember 2025-06-30 0001269026 us-gaap:TreasuryStockCommonMember 2025-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001269026 us-gaap:RetainedEarningsMember 2025-06-30 0001269026 2025-06-30 0001269026 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001269026 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001269026 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001269026 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001269026 2024-01-01 2024-03-31 0001269026 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001269026 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001269026 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001269026 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001269026 2024-04-01 2024-06-30 0001269026 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001269026 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001269026 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001269026 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001269026 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001269026 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001269026 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001269026 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001269026 2025-01-01 2025-03-31 0001269026 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001269026 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001269026 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001269026 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001269026 2025-04-01 2025-06-30 0001269026 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001269026 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001269026 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001269026 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001269026 us-gaap:PreferredStockMember 2024-09-30 0001269026 us-gaap:CommonStockMember 2024-09-30 0001269026 us-gaap:TreasuryStockCommonMember 2024-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001269026 us-gaap:RetainedEarningsMember 2024-09-30 0001269026 2024-09-30 0001269026 us-gaap:PreferredStockMember 2025-09-30 0001269026 us-gaap:CommonStockMember 2025-09-30 0001269026 us-gaap:TreasuryStockCommonMember 2025-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001269026 us-gaap:RetainedEarningsMember 2025-09-30 0001269026 2024-05-28 2024-05-28 0001269026 us-gaap:SubsequentEventMember SINT:TwoThousandTwentyFiveATMAgreementMember 2025-10-03 2025-10-03 0001269026 us-gaap:SubsequentEventMember SINT:ArmorFacilityMember 2025-10-01 2025-10-31 0001269026 2025-02-19 0001269026 SINT:SinapticSurgicalMember 2025-07-01 2025-07-01 0001269026 SINT:SinapticSurgicalMember 2025-07-01 0001269026 SINT:SinapticHoldingsLLCMember 2025-07-01 2025-07-01 0001269026 SINT:SinapticHoldingsLLCMember 2025-07-01 0001269026 SINT:CommonStockPrivatePlacementMember 2025-01-01 2025-09-30 0001269026 SINT:WarrantsMember 2025-01-01 2025-09-30 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2025-09-30 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2025-09-30 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2025-09-30 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2025-09-30 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2024-12-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2024-12-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2024-12-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2024-12-31 0001269026 us-gaap:FairValueInputsLevel3Member SINT:CommonStockWarrantsMember 2023-12-31 0001269026 us-gaap:FairValueInputsLevel3Member SINT:CommonStockWarrantsMember 2024-01-01 2024-09-30 0001269026 us-gaap:FairValueInputsLevel3Member SINT:CommonStockWarrantsMember 2024-09-30 0001269026 us-gaap:FairValueInputsLevel3Member SINT:CommonStockWarrantsMember 2024-12-31 0001269026 us-gaap:FairValueInputsLevel3Member SINT:CommonStockWarrantsMember 2025-01-01 2025-09-30 0001269026 us-gaap:FairValueInputsLevel3Member SINT:CommonStockWarrantsMember 2025-09-30 0001269026 srt:MinimumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 srt:MaximumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 srt:MinimumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 srt:MaximumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 srt:MinimumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedTermMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 srt:MaximumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedTermMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 srt:MinimumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedTermMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 srt:MaximumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedTermMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 SINT:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 SINT:CommonStockWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 srt:MinimumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 srt:MaximumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember SINT:BlackScholesMertonValuationModelMember 2025-09-30 0001269026 srt:MinimumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 srt:MaximumMember SINT:CommonStockWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember SINT:BlackScholesMertonValuationModelMember 2024-12-31 0001269026 SINT:InsurancePremiumFinanceArrangementsMember 2024-06-01 2024-06-30 0001269026 SINT:InsurancePremiumFinanceArrangementsMember 2024-06-30 0001269026 SINT:DirectorAndOfficerProfessionalLiabilityInsuranceMember SINT:InsurancePremiumFinanceArrangementsMember 2025-03-01 2025-03-31 0001269026 SINT:DirectorAndOfficerProfessionalLiabilityInsuranceMember SINT:InsurancePremiumFinanceArrangementsMember 2025-03-31 0001269026 SINT:DirectorAndOfficerProfessionalLiabilityInsuranceMember SINT:InsurancePremiumFinanceArrangementsMember 2025-09-30 0001269026 SINT:DirectorAndOfficerProfessionalLiabilityInsuranceMember SINT:InsurancePremiumFinanceArrangementsMember 2025-05-01 2025-05-31 0001269026 SINT:DirectorAndOfficerProfessionalLiabilityInsuranceMember SINT:InsurancePremiumFinanceArrangementsMember 2025-01-01 2025-09-30 0001269026 SINT:InducementLetterMember 2025-02-25 0001269026 SINT:InducementLetterMember 2025-09-08 0001269026 SINT:InducementLetterMember 2025-09-08 2025-09-08 0001269026 2025-09-08 2025-09-08 0001269026 2025-02-20 2025-02-20 0001269026 2025-02-20 0001269026 SINT:PreFundedWarrantMember 2025-02-20 0001269026 us-gaap:WarrantMember 2025-02-20 0001269026 us-gaap:WarrantMember 2025-02-20 2025-02-20 0001269026 SINT:TwoThousandTwentyFourAprilRegisteredOfferingMember 2024-04-05 2024-04-05 0001269026 SINT:TwoThousandTwentyFourAprilRegisteredOfferingMember 2024-04-05 0001269026 SINT:TwoThousandTwentyFourMarchRegisteredOfferingMember 2024-03-26 2024-03-26 0001269026 SINT:TwoThousandTwentyFourMarchRegisteredOfferingMember 2024-03-26 0001269026 SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 2024-02-02 0001269026 SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:CommonUnitsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 2024-02-02 0001269026 SINT:PreFundedWarrantUnitsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 2024-02-02 0001269026 SINT:CommonUnitsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:PreFundedWarrantUnitsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:PreFundedWarrantMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:ClassEWarrantsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:ClassFWarrantsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 srt:MaximumMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:PlacementAgentWarrantsMember SINT:TwoThousandTwentyFourFebruaryRegisteredOfferingMember 2024-02-02 0001269026 SINT:ATMAgreementMember SINT:MaximGroupLLCMember 2021-02-25 0001269026 srt:MaximumMember SINT:ATMAgreementMember SINT:MaximGroupLLCMember 2021-02-25 2021-02-25 0001269026 SINT:ATMAgreementMember 2024-07-11 2024-07-11 0001269026 SINT:ATMAgreementMember 2024-01-01 2024-12-31 0001269026 SINT:TwoThousandAndTwentyOneEquityDistributionAgreementMember SINT:MaximGroupLLCMember 2024-01-01 2024-12-31 0001269026 2024-01-01 2024-12-31 0001269026 2023-01-01 2023-12-31 0001269026 us-gaap:EmployeeStockOptionMember 2025-09-30 0001269026 SINT:NonExecutiveMember 2025-01-01 2025-09-30 0001269026 us-gaap:EmployeeStockOptionMember 2025-09-30 0001269026 SINT:EmployeeStockGrantsMember 2025-09-30 0001269026 SINT:EmployeeStockGrantsMember 2025-01-01 2025-09-30 0001269026 SINT:ArmorFacilityMember 2025-09-30 0001269026 SINT:ArmorFacilityMember 2025-01-01 2025-09-30 0001269026 SINT:ArmorFacilityMember 2024-01-01 2024-12-31 0001269026 us-gaap:SubsequentEventMember SINT:ArmorFacilityMember 2025-10-31 0001269026 SINT:ResearchCollaborationAgreementMember 2025-01-01 2025-09-30 0001269026 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember SINT:ResearchCollaborationAgreementMember 2025-09-30 0001269026 us-gaap:SubsequentEventMember SINT:TwoThousandTwentyFiveATMAgreementMember 2025-10-03 0001269026 us-gaap:SubsequentEventMember SINT:SubleaseAgreementMember 2025-10-30 2025-10-30 0001269026 srt:MinimumMember us-gaap:SubsequentEventMember SINT:SubleaseAgreementMember 2025-10-30 2025-10-30 0001269026 srt:MaximumMember us-gaap:SubsequentEventMember SINT:SubleaseAgreementMember 2025-10-30 2025-10-30 0001269026 us-gaap:SubsequentEventMember SINT:SubleaseAgreementMember 2025-10-30 iso4217:USD shares iso4217:USD shares pure utr:sqft SINT:Segment false Q3 --12-31 0001269026 10-Q true 2025-09-30 2025 false 001-33624 SINTX Technologies, Inc. DE 84-1375299 1885 West 2100 South Salt Lake City UT 84119 (801) 839-3500 Common Stock SINT NASDAQ Yes Yes Non-accelerated Filer true false false 3851956 0.01 6250000 3598000 4200 61000.0 120000 196000 577000 475000 447000 502000 7394000 4771000 402000 465000 507000 922000 150000 16000 302000 2536000 3159000 73000 80000 11364000 9413000 203000 299000 1050000 986000 59000 32000 870000 208000 384000 456000 1781000 1000 4347000 1982000 2949000 3537000 7296000 5519000 0.01 0.01 130000000 130000000 19 19 19 19 0.01 0.01 130000000 130000000 50 50 50 50 0.01 0.01 130000000 130000000 180 180 180 180 0.01 0.01 250000000 250000000 3666280 1342853 3615856 1342853 36000 13000 50424 133000 294052000 285619000 -289887000 -281738000 4068000 3894000 11364000 9413000 150000 367000 541000 1054000 58000 432000 187000 1291000 208000 799000 728000 2345000 115000 210000 455000 657000 93000 589000 273000 1688000 1264000 796000 3618000 4492000 2102000 802000 4836000 2997000 59000 87000 100000 589000 4457000 4457000 407000 407000 23000 448000 122000 1061000 3448000 6997000 8676000 14003000 -3355000 -6408000 -8403000 -12315000 13000 9000 40000 15000 43000 24000 130000 66000 -20000 327000 -8000 -214000 173000 -166000 3459000 550000 1000 3000 34000 -184000 169000 254000 2986000 -3539000 -6239000 -8149000 -9329000 -3539000 -6239000 -8149000 -9329000 6719000 6719000 -10258000 -6239000 -14868000 -9329000 -1.19 -6.96 -3.38 -17.30 -2.27 -2.79 -3.46 -6.96 -6.17 -17.30 -1.19 -6.96 -3.38 -19.59 -2.27 -2.79 -3.46 -6.96 -6.17 -19.59 2963539 896305 2411004 539252 2963539 897323 2411179 656468 256 26603 279486000 -270714000 8772000 50000 50000 165797 2000 1582000 1584000 406000 406000 63000 1000 -1000 -886000 -886000 256 255400 3000 281523000 -271600000 9926000 14 15000 15000 358000 4000 1104000 1108000 79 1000 1000 -11 2881 131967 -2204000 -2204000 245 748341 7000 282643000 -273804000 8846000 10000 10000 595560 6000 2958000 2964000 4 -1048 -6239000 -6239000 249 1342853 13000 285611000 -280043000 5581000 249 1342853 13000 285619000 -281738000 3894000 2264 177000 177000 1171189 12000 4387000 4399000 5 -86000 -86000 -2292000 -2292000 249 2516311 25000 -86000 290183000 -284030000 6092000 53932 1000 279000 280000 -19000 -19000 20928 -47000 -47000 -2318000 -2318000 249 2591171 26000 -133000 290443000 -286348000 3988000 249 2591171 26000 -133000 290443000 -286348000 3988000 35004 888000 888000 216450 2000 680000 682000 128000 1000 -1000 695655 7000 2042000 2049000 -6719000 -6719000 6719000 6719000 -3539000 -3539000 249 3666280 36000 -133000 294052000 -289887000 4068000 249 3666280 36000 -133000 294052000 -289887000 4068000 -8149000 -9329000 245000 727000 64000 4457000 246000 428000 25000 11000 4000 739000 75000 606000 -166000 3459000 -1000 13000 352000 -8000 13000 -332000 -70000 -241000 -110000 -171000 247000 -788000 34000 -2000 -275000 -396000 -6227000 -7518000 143000 544000 750000 320000 352000 20000 4000 955000 -204000 3366000 4380000 6075000 3624000 133000 206000 2000 153000 247000 7924000 9196000 2652000 1474000 3598000 3340000 6250000 4814000 180000 335000 6719000 13000 307000 1000 40000 15000 <p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_z7pOeUIdKNo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82B_zS7vhjhJ4BHg">Organization and Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The condensed consolidated financial statements include the accounts of SINTX Technologies, Inc. (“SINTX”, or the “Company”) and its wholly-owned subsidiaries, SINTX Armor, Inc. (“SINTX Armor”), SINTX Agribiotech, Inc., Sinaptic Surgical, LLC, and Technology Assessment and Transfer, Inc. (TA&amp;T) through February 19, 2025 (see Note 2), which are collectively referred to as “we” or the “Company.” SINTX Technologies is an advanced ceramics company formed in December 1996 that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX provides biomedical solutions for medical devices specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SINTX Core Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Biomedical Applications</b>: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the U.S., Europe, South America and Asia. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. More recently, in October 2025, SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot &amp; Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. These next-generation implants blend cutting-edge biomaterials science with surgical precision and are designed to elevate standards in orthopedic procedures. SINTX silicon nitride products can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that silicon nitride has a superb combination of properties that make it suited for long-term human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers- all of which have well-known practical limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. Bacterial infection of any biomaterial implants is always a concern. SINTX silicon nitride has been shown to be resistant to bacterial colonization and biofilm formation, making it antibacterial. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature reports. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Antipathogenic Applications</b>: Today, there is a global need to improve protection against pathogens in everyday life. SINTX believes that by incorporating its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. The discovery in 2020 that SINTX silicon nitride inactivates SARS-CoV-2, the virus which causes the disease COVID-19, has opened new markets and applications for our material. We presently manufacture advanced ceramic powders and components in our manufacturing facilities based in Salt Lake City, Utah.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO 9001:2015, ISO 13485:2016 certified, and ASD9100D certified. The Company’s products are primarily sold in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgyftIDRvHOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zM9ZRSJ0aNFc">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 19, 2025. The results of operations for the nine months ended September 30, 2025, are not necessarily indicative of the results to be expected for the year ending December 31, 2025. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znht8EaMiCRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zZ1O4fOKie5d">Segment Information</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates as <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20250930_ziprHg6ZCJub" title="Number of operating segment">one</span> operating segment. Operating segments are defined as components of an entity for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates financial information and resources and assesses the performance of these resources on a consolidated basis. There is no expense or asset information that is supplemental to information disclosed within the consolidated financial statements that is regularly provided to the CODM. The allocation of resources and assessment of performance of the operating segment is based on consolidated net loss and functional expenses as reported on our condensed consolidated statements of operations and comprehensive loss. Because the Company operates as one operating segment, financial segment information, including expense and asset information, can be found in the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--ReverseStockSplitPolicyTextBlock_zLkfu8cPAY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zSxYE7Ps46qi">Reverse Stock Split</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 28, 2024, the Company effected a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240528__20240528_zEjzOgtIzy8i" title="Reverse stock split, description">1-for-200 reverse stock split</span> of the Company’s common stock. The par value and the authorized shares of the common and preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed consolidated financial statements have been adjusted retroactively to reflect the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--UseOfEstimates_zVZ61hPXiXGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zzqhj3AGRkad">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2025, the most significant estimate relates to derivative liabilities relating to common stock warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyQCirvCEoGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zz5zs8fr4m6a">Reclassification</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain other prior period balances have been reclassified to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--LiquidityAndCapitalResourcesPolicyTextBlock_zYB35adDKUj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zixBsgInzhrh">Liquidity and capital resources</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, decrease expenses and raise additional funding. We continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed and may not be available to the Company on favorable terms and may involve restrictive covenants. If the Company is not able to obtain additional debt or equity financing, the impact on the Company will be material and adverse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The board of directors, together with management, remains focused on advancing the Company’s business strategy and focus. We are concentrating our resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility. Through this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot &amp; Ankle Osteotomy Wedge System, our aim is to deliver meaningful innovations to the medical community. By focusing on partnerships and collaborations with healthcare institutions and industry leaders, SINTX is positioned to expand its footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part of the Company’s ongoing strategic review of its operations aimed at improving operational efficiency and reducing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 12, 2024, the board of directors approved a plan to cease efforts to make the armor plant operational. This decision was made to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals. The armor plant had not been fully operational since the acquisition of the armor equipment in July 2021 and had been completely shut down since October 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 2 to the condensed consolidated financial statements, on February 19, 2025, the Company sold to Tethon all the issued and outstanding shares of TA&amp;T in exchange for the assumption by Tethon of the outstanding liabilities of TA&amp;T.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in further detail above, in October 2025, the Company received FDA 510(k) clearance for a new foot and ankle osteotomy wedge system, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. Revenue is expected to begin during the first half of 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 14 to the condensed consolidated financial statements, in October 2025, the Company entered into the 2025 ATM Agreement to sell shares of its common stock from time to time, through an “at the market offering” program, having an aggregate offering price of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20251003__20251003__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7jFf3PBrunh" title="Offering price">6,413,876</span> was filed with the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 12 to the condensed consolidated financial statements, in October 2025, the Company entered into a sublease agreement to lease the SINTX armor facility, that is expected to save the Company approximately $<span id="xdx_901_eus-gaap--SubleaseIncome_c20251001__20251031__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcMsDIamqaTg" title="Sublease income">950,000</span> over the sublease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that based on its existing capital resources and funds generated by operations, there is no significant uncertainty of the Company’s ability to continue as a going concern through at least November 12, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIG5uhbCxkg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zkM3altzw339">Recent Accounting Pronouncements</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” on the topic of income taxes. The standard requires additional disclosure for income taxes. These requirements include: (i) requiring a public entity to disclose specific categories in the rate reconciliation; (ii) disclosure of additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate); (iii) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; (iv) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5% of total income taxes paid (net of refunds received); (v) annual disclosure of income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign; and (vi) annual disclosure of income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. For public entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company will adopt this guidance in fiscal 2025 and is in the process of evaluating the new requirements. As a result, the Company has not yet determined the impact this new ASU will have on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses,” which requires public business entities, such as the Company, to provide disaggregated disclosure of specific natural expense categories underlying certain income statement expense line items in the notes to the financial statements. The standard identifies five required natural expense categories for disaggregation—employee compensation, depreciation, amortization, inventory expense, and other manufacturing expenses—along with a residual “other” category for remaining amounts within relevant expense captions (e.g., cost of sales, selling, general and administrative expenses). ASU 2024-03 does not alter the expense captions presented on the face of the income statement but enhances footnote disclosures to improve transparency. The standard is effective for annual periods beginning after December 15, 2026, with early adoption permitted, and must be applied prospectively, though retrospective application is optional. An update in ASU 2025-01 clarified that interim period disclosures are not required until annual periods beginning after December 15, 2027. The Company is in the process of evaluating the impact of ASU 2024-03 on its consolidated financial statements. We expect adoption to necessitate modifications to our financial reporting processes and systems to capture and disclose the required disaggregated expense information in the footnotes. Management anticipates that this will enhance the granularity of expense disclosures but does not expect a material effect on our reported financial position or results of operations. We are reviewing our current expense classification practices and data collection capabilities to ensure compliance with the new requirements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined that recently issued accounting standards, other than the above discussed, will not have a material impact on its consolidated financial position, results of operations or cash flows.</span></p> <p id="xdx_855_zQxIYlgiATMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgyftIDRvHOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zM9ZRSJ0aNFc">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 19, 2025. The results of operations for the nine months ended September 30, 2025, are not necessarily indicative of the results to be expected for the year ending December 31, 2025. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_znht8EaMiCRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zZ1O4fOKie5d">Segment Information</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates as <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20250930_ziprHg6ZCJub" title="Number of operating segment">one</span> operating segment. Operating segments are defined as components of an entity for which separate financial information is regularly evaluated by the chief operating decision maker (“CODM”), which is the Company’s Chief Executive Officer, in deciding how to allocate resources and assess performance. The Company’s CODM evaluates financial information and resources and assesses the performance of these resources on a consolidated basis. There is no expense or asset information that is supplemental to information disclosed within the consolidated financial statements that is regularly provided to the CODM. The allocation of resources and assessment of performance of the operating segment is based on consolidated net loss and functional expenses as reported on our condensed consolidated statements of operations and comprehensive loss. Because the Company operates as one operating segment, financial segment information, including expense and asset information, can be found in the condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 <p id="xdx_84F_ecustom--ReverseStockSplitPolicyTextBlock_zLkfu8cPAY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zSxYE7Ps46qi">Reverse Stock Split</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 28, 2024, the Company effected a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240528__20240528_zEjzOgtIzy8i" title="Reverse stock split, description">1-for-200 reverse stock split</span> of the Company’s common stock. The par value and the authorized shares of the common and preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed consolidated financial statements have been adjusted retroactively to reflect the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1-for-200 reverse stock split <p id="xdx_845_eus-gaap--UseOfEstimates_zVZ61hPXiXGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zzqhj3AGRkad">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2025, the most significant estimate relates to derivative liabilities relating to common stock warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyQCirvCEoGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zz5zs8fr4m6a">Reclassification</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain other prior period balances have been reclassified to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--LiquidityAndCapitalResourcesPolicyTextBlock_zYB35adDKUj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zixBsgInzhrh">Liquidity and capital resources</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, decrease expenses and raise additional funding. We continue to seek opportunities to raise additional funding through equity and/or debt financing. However, such funding is not guaranteed and may not be available to the Company on favorable terms and may involve restrictive covenants. If the Company is not able to obtain additional debt or equity financing, the impact on the Company will be material and adverse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The board of directors, together with management, remains focused on advancing the Company’s business strategy and focus. We are concentrating our resources on high-growth areas within the healthcare sector where our proprietary materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique strength, durability, and biocompatibility. Through this transformation, as demonstrated by the recent FDA 510(k) clearance of our SiNAPTIC® Foot &amp; Ankle Osteotomy Wedge System, our aim is to deliver meaningful innovations to the medical community. By focusing on partnerships and collaborations with healthcare institutions and industry leaders, SINTX is positioned to expand its footprint in the medical device sector and drive shareholder value through sustainable, high-impact innovations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2024, the board of directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part of the Company’s ongoing strategic review of its operations aimed at improving operational efficiency and reducing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 12, 2024, the board of directors approved a plan to cease efforts to make the armor plant operational. This decision was made to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals. The armor plant had not been fully operational since the acquisition of the armor equipment in July 2021 and had been completely shut down since October 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 2 to the condensed consolidated financial statements, on February 19, 2025, the Company sold to Tethon all the issued and outstanding shares of TA&amp;T in exchange for the assumption by Tethon of the outstanding liabilities of TA&amp;T.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in further detail above, in October 2025, the Company received FDA 510(k) clearance for a new foot and ankle osteotomy wedge system, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. Revenue is expected to begin during the first half of 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 14 to the condensed consolidated financial statements, in October 2025, the Company entered into the 2025 ATM Agreement to sell shares of its common stock from time to time, through an “at the market offering” program, having an aggregate offering price of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20251003__20251003__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7jFf3PBrunh" title="Offering price">6,413,876</span> was filed with the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 12 to the condensed consolidated financial statements, in October 2025, the Company entered into a sublease agreement to lease the SINTX armor facility, that is expected to save the Company approximately $<span id="xdx_901_eus-gaap--SubleaseIncome_c20251001__20251031__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcMsDIamqaTg" title="Sublease income">950,000</span> over the sublease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that based on its existing capital resources and funds generated by operations, there is no significant uncertainty of the Company’s ability to continue as a going concern through at least November 12, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 6413876 950000 <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIG5uhbCxkg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zkM3altzw339">Recent Accounting Pronouncements</span> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” on the topic of income taxes. The standard requires additional disclosure for income taxes. These requirements include: (i) requiring a public entity to disclose specific categories in the rate reconciliation; (ii) disclosure of additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate); (iii) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; (iv) annual disclosure of the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5% of total income taxes paid (net of refunds received); (v) annual disclosure of income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign; and (vi) annual disclosure of income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. For public entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company will adopt this guidance in fiscal 2025 and is in the process of evaluating the new requirements. As a result, the Company has not yet determined the impact this new ASU will have on its disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses,” which requires public business entities, such as the Company, to provide disaggregated disclosure of specific natural expense categories underlying certain income statement expense line items in the notes to the financial statements. The standard identifies five required natural expense categories for disaggregation—employee compensation, depreciation, amortization, inventory expense, and other manufacturing expenses—along with a residual “other” category for remaining amounts within relevant expense captions (e.g., cost of sales, selling, general and administrative expenses). ASU 2024-03 does not alter the expense captions presented on the face of the income statement but enhances footnote disclosures to improve transparency. The standard is effective for annual periods beginning after December 15, 2026, with early adoption permitted, and must be applied prospectively, though retrospective application is optional. An update in ASU 2025-01 clarified that interim period disclosures are not required until annual periods beginning after December 15, 2027. The Company is in the process of evaluating the impact of ASU 2024-03 on its consolidated financial statements. We expect adoption to necessitate modifications to our financial reporting processes and systems to capture and disclose the required disaggregated expense information in the footnotes. Management anticipates that this will enhance the granularity of expense disclosures but does not expect a material effect on our reported financial position or results of operations. We are reviewing our current expense classification practices and data collection capabilities to ensure compliance with the new requirements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined that recently issued accounting standards, other than the above discussed, will not have a material impact on its consolidated financial position, results of operations or cash flows.</span></p> <p id="xdx_801_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zleFYzLgooH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_82C_zNKqt9wTExRh">Disposition of TA&amp;T</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2025, the Company entered into an Entity Acquisition Agreement (the “Agreement”) with Tethon Corporation (“Tethon”), pursuant to which the Company sold to Tethon all the issued and outstanding shares of TA&amp;T in exchange for the assumption by Tethon of the outstanding liabilities of TA&amp;T. The disposal did not represent a strategic shift that will have a major effect on the Company’s operations and financials and, therefore, did not qualify for discontinued operations treatment under ASC 205-20.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zdPTYe9JAPgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&amp;T at the date of sale that were transferred to the Tethon (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zB6H6Mcf9qI7" style="display: none">Schedule of Major Classes of Assets and Liabilities of TA &amp; T at the Date of Sale</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250219_zIrOz53Jut96" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 19, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maAzIjF_zZmA7yFkAolj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iI_pn3n3_maAzIjF_zzCShpYXfom1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Inventories</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsReceivableNet_iI_pn3n3_maAzIjF_z4EjbVHWwRV4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_maAzIjF_zJLjmyrjtQ0d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_maAzIjF_zqrnfsrAoKH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssets_iI_pn3n3_maAzIjF_zu95i85wPIwj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Assets_iTI_pn3n3_mtAzIjF_maANzJEJ_zZ3T7HipUD92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">743</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_iNI_pn3n3_di_maBCRIAzal5_zKSq7gBRIJg5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_iNI_pn3n3_di_maBCRIAzal5_z3kn8EsGmqaa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(275</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_maBCRIAzal5_z3Pjk2CWiMDh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(384</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_iNI_pn3n3_di_maBCRIAzal5_zVi27E3nU4h5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(34</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNI_pn3n3_di_msANzJEJ_mtBCRIAzal5_zwvnHvUkzE21" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(719</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--AssetsNet_iTI_pn3n3_mtANzJEJ_zZc0bKrufKhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net assets sold</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zJmNVebBlu4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No consideration was paid other than the assumption by Tethon of the above liabilities. No significant transaction costs were incurred. No earnout or other contingent consideration arrangements were included in the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zdPTYe9JAPgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&amp;T at the date of sale that were transferred to the Tethon (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zB6H6Mcf9qI7" style="display: none">Schedule of Major Classes of Assets and Liabilities of TA &amp; T at the Date of Sale</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250219_zIrOz53Jut96" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 19, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maAzIjF_zZmA7yFkAolj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iI_pn3n3_maAzIjF_zzCShpYXfom1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Inventories</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsReceivableNet_iI_pn3n3_maAzIjF_z4EjbVHWwRV4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_maAzIjF_zJLjmyrjtQ0d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right of use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_maAzIjF_zqrnfsrAoKH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssets_iI_pn3n3_maAzIjF_zu95i85wPIwj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Assets_iTI_pn3n3_mtAzIjF_maANzJEJ_zZ3T7HipUD92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">743</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_iNI_pn3n3_di_maBCRIAzal5_zKSq7gBRIJg5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_iNI_pn3n3_di_maBCRIAzal5_z3kn8EsGmqaa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(275</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_maBCRIAzal5_z3Pjk2CWiMDh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(384</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_iNI_pn3n3_di_maBCRIAzal5_zVi27E3nU4h5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(34</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNI_pn3n3_di_msANzJEJ_mtBCRIAzal5_zwvnHvUkzE21" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(719</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--AssetsNet_iTI_pn3n3_mtANzJEJ_zZc0bKrufKhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net assets sold</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4000 8000 91000 376000 248000 16000 743000 26000 275000 384000 34000 719000 24000 <p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_z8csLP2Miv96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_828_zPcOMN0bFXjd">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2025, the Company entered into an Asset Purchase Agreement with Sinaptic Surgical, LLC (“Sinaptic Surgical”) and Sinaptic Holdings, LLC (“Holdings”), pursuant to which the Company agreed to purchase substantially all the assets and assume certain liabilities of Sinaptic Surgical. As consideration for the purchase of the assets under the Asset Purchase Agreement, the Company agreed to issue to Sinaptic Surgical warrants to purchase <span id="xdx_900_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20250701__20250701__us-gaap--BusinessAcquisitionAxis__custom--SinapticSurgicalMember_zpUieOBUg2Fc" title="Warrants to purchase shares">325,000</span> shares of the Company’s common stock (the “Warrants”). The Warrants expire five years from the date of issue and have an exercise price of $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250701__us-gaap--BusinessAcquisitionAxis__custom--SinapticSurgicalMember_zWCu1UNPWha4" title="Warrants to purchase exercise price per share">6.30</span> per share. The Warrants will become exercisable upon the achievement of certain milestones prior to the expiration of the Warrants. In connection with the Asset Purchase Agreement, Sinaptic Surgical purchased <span id="xdx_907_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20250701__20250701__us-gaap--BusinessAcquisitionAxis__custom--SinapticHoldingsLLCMember_z1MataXxF6C3" title="Warrants to purchase shares">216,450</span> shares of the Company’s common stock at a purchase price of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250701__us-gaap--BusinessAcquisitionAxis__custom--SinapticHoldingsLLCMember_zEnwdSk8lzu" title="Warrants to purchase exercise price per share">3.465</span> per share in a private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value for the acquired intangible asset was estimated utilizing the income approach, which involves the use of significant estimates and assumptions including projected revenue growth rates, projected earnings, and discount rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zDv9cuR0gJWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the consideration transferred, the estimated fair value of the assets acquired, and liabilities assumed, at the acquisition date (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_z3doh4LPc0Dj" style="display: none">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250930_zDCN60qOoR17" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amounts recognized as of the acquisition date</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Fair value of consideration transferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--CommonStockPrivatePlacementMember_zVdnvBCyG7Ke" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Common stock private placement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">682</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--WarrantsMember_zDIgZoOXzZtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Warrants (included in derivative liabilities)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">495</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_zaOjzfKuO8l4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total consideration transferred</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Recognized amounts of identifiable assets acquired and liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Cash</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20250930_zgGyh7WbPDc2" style="text-align: right" title="Cash">750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Intangibles</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_pn3n3_c20250930_z2k5rq7LPmNk" style="border-bottom: Black 1pt solid; text-align: right" title="Intangibles">145</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify">Total assets acquired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_iTI_pn3n3_c20250930_zVGxuzJv0cef" style="text-align: right" title="Total assets acquired">895</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Accounts payable and other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_iNI_pn3n3_di_c20250930_zzoXcKjc9ZKd" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable and other accrued expenses">(20</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total identifiable net assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_c20250930_zRtk5ZjcBam2" style="border-bottom: Black 1pt solid; text-align: right" title="Total identifiable net assets">875</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iI_pn3n3_c20250930_ziRJ4UeI2Ea" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill">302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zEFoqbJru0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized goodwill of $<span id="xdx_905_eus-gaap--Goodwill_iI_c20250930_zRDU5KksFqpf" title="Goodwill">302,000</span>, which reflects the future benefits of certain synergies, and regulatory and commercialization strategies. Acquired intangible assets are being amortized over the estimated useful life of five years on a straight-line basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 325000 6.30 216450 3.465 <p id="xdx_897_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zDv9cuR0gJWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the consideration transferred, the estimated fair value of the assets acquired, and liabilities assumed, at the acquisition date (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_z3doh4LPc0Dj" style="display: none">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250930_zDCN60qOoR17" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amounts recognized as of the acquisition date</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Fair value of consideration transferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--CommonStockPrivatePlacementMember_zVdnvBCyG7Ke" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Common stock private placement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">682</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--BusinessAcquisitionAxis__custom--WarrantsMember_zDIgZoOXzZtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Warrants (included in derivative liabilities)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">495</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_zaOjzfKuO8l4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total consideration transferred</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,177</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Recognized amounts of identifiable assets acquired and liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Cash</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20250930_zgGyh7WbPDc2" style="text-align: right" title="Cash">750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Intangibles</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_pn3n3_c20250930_z2k5rq7LPmNk" style="border-bottom: Black 1pt solid; text-align: right" title="Intangibles">145</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: justify">Total assets acquired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_iTI_pn3n3_c20250930_zVGxuzJv0cef" style="text-align: right" title="Total assets acquired">895</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Accounts payable and other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_iNI_pn3n3_di_c20250930_zzoXcKjc9ZKd" style="border-bottom: Black 1pt solid; text-align: right" title="Accounts payable and other accrued expenses">(20</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total identifiable net assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_c20250930_zRtk5ZjcBam2" style="border-bottom: Black 1pt solid; text-align: right" title="Total identifiable net assets">875</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iI_pn3n3_c20250930_ziRJ4UeI2Ea" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill">302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 682000 495000 1177000 750000 145000 895000 20000 875000 302000 302000 <p id="xdx_804_eus-gaap--EarningsPerShareTextBlock_zzyTj3FWCWSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_828_z0RAynv9DXm9">Basic and Diluted Net Income (Loss) per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. The Company had potentially dilutive securities of approximately <span id="xdx_902_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pn5n6_c20250101__20250930_zuDEHyFNkRi1" title="Dilutive securities">3.3</span> million and <span id="xdx_903_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pn5n6_c20240101__20240930_zUbJ8KZ6yzhi" title="Dilutive securities">0.1</span> million as of September 30, 2025, and 2024, respectively, that were not included in the fully diluted loss per share calculation because they would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkYYc1GamXP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the three months ended September 30, 2025, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zTNpTatZhh8g" style="display: none">Schedule of Basic and Diluted Loss Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetLossBasicCalculation_pn3n3_c20250701__20250930_z0dOc8GSHEE6" style="width: 14%; text-align: right" title="Net loss, basic calculation">(3,539</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20250701__20250930_zizavnvC9OO3" style="width: 14%; text-align: right" title="Net loss, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--NetLossDilutedCalculation_pn3n3_c20250701__20250930_zTYVHW9DdtTa" style="width: 14%; text-align: right" title="Net loss, diluted calculation">(3,539</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20250701__20250930_zqY1S2pR3zB" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation">(6,719</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20250701__20250930_zVC3AS9shuoi" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20250701__20250930_zbRlcY0h9hV9" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation">(6,719</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20250701__20250930_zfgo2tCsZ8yi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, basic calculation">(10,258</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--NetLossAttributableToCommonStockholdersEffectOfDilutiveWarrantSecurities_pn3n3_c20250701__20250930_zw75o7J9ZMJg" style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: right" title="Net loss attributable to common stockholders, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20250701__20250930_zC64606EWEaj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, diluted calculation">(10,258</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250701__20250930_zVE4N4yLEv62" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">2,963,539</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250701__20250930_zpXfuSGlKRF9" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">     <span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250701__20250930_zoILTkVOV2B8" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">2,963,539</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20250701__20250930_z8hw2chpjpw5" style="text-align: right" title="Net loss per common share: basic calculation">(1.19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20250701__20250930_zKoZYxi9Aq49" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20250701__20250930_zbtx9mBOidIa" style="text-align: right" title="Net loss per common share: diluted calculation">(1.19</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20250701__20250930_zE1583aM8Ghd" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation">(2.27</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20250701__20250930_zZSvRZhW7pL6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20250701__20250930_zewswi6jOYzh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation">(2.27</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasic_pid_c20250701__20250930_zjBTK6L00OQ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, basic calculation">(3.46</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetLossAttributableToCommonStockholdersEffectOfDilutiveWarrantSecurities_pid_c20250701__20250930_zstmS2dmtSSf" style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: right" title="Net loss attributable to common stockholders, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EarningsPerShareDiluted_pid_c20250701__20250930_zrF530P2lmb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, diluted calculation">(3.46</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the nine months ended September 30, 2025, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_904_ecustom--NetLossBasicCalculation_pn3n3_c20250101__20250930_zgR8iFcxYs53" title="Net loss, basic calculation">(8,149</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90F_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20250101__20250930_zHGlcQkPJzPg" title="Net loss, effect of dilutive warrant securities">(1</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90F_ecustom--NetLossDilutedCalculation_pn3n3_c20250101__20250930_zyco65PiqPQi" title="Net loss, diluted calculation">(8,150</span></td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deemed dividend related to warrant inducement</p></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Net loss, basic calculation"><span id="xdx_901_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20250101__20250930_zgcj6V0W5OQh" title="Deemed dividend related to warrant inducement, basic calculation">(6,719</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20250101__20250930_zknpTcZBvGXd" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Net loss, diluted calculation"><span id="xdx_902_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20250101__20250930_zeDsz6Q2sYp7" title="Deemed dividend related to warrant inducement, diluted calculation">(6,719</span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20250101__20250930_zbizJqOJ9odd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, basic calculation">(14,868</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeEffectOfDilutiveWarrantSecurities_pn3n3_c20250101__20250930_zj79bBt32UMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, effect of dilutive warrant securities">(1</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20250101__20250930_zsm92fomBwsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, diluted calculation">(14,869</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250930_zib7CDDArKHd" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">2,411,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250101__20250930_zTybjCJEET7k" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250930_zNTO6p0uGROd" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">2,411,179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20250101__20250930_z41QRbtHChtc" style="text-align: right" title="Net loss per common share: basic calculation">(3.38</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20250101__20250930_zhILUbneNH9g" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(5.71</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20250101__20250930_zsEMyeuLSOT6" style="text-align: right" title="Net loss per common share: diluted calculation">(3.38</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20250101__20250930_zOtqvv2zo9X8" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation">(2.79</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20250101__20250930_zOkOBSYcX5Aj" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20250101__20250930_z0lsXYim4Eaf" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation">(2.79</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250930_zspAWmtyIBNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: basic calculation">(6.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--NetLossAttributableToCommonStockholdersEffectOfDilutiveWarrantSecurities_pid_c20250101__20250930_z5i9M6F4jjy1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, effect of dilutive warrant securities">(5.71</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250930_zBGdkJyRHPYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: diluted calculation">(6.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the three months ended September 30, 2024, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--NetLossBasicCalculation_pn3n3_c20240701__20240930_z5jG49yVuSTe" style="width: 14%; text-align: right" title="Net loss, basic calculation">(6,239</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20240701__20240930_zavCTtm7HVFh" style="width: 14%; text-align: right" title="Net loss, effect of dilutive warrant securities">(4</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetLossDilutedCalculation_pn3n3_c20240701__20240930_zNVSj2t9DTf4" style="width: 14%; text-align: right" title="Net loss, diluted calculation">(6,243</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20240701__20240930_zkKUFinBwPMj" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20240701__20240930_zFfGE6N9eRDh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20240701__20240930_z719Vrc2kHb1" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240701__20240930_zjHfljbQQFoi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, basic calculation">(6,239</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeEffectOfDilutiveWarrantSecurities_pn3n3_c20240701__20240930_zWaCrzNW1i2g" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, effect of dilutive warrant securities">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20240701__20240930_zqP6nUJpelfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, diluted calculation">(6,243</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_z9LsTTTcKbpb" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">896,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240701__20240930_zdN9JBuA1M69" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">1,018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_zRfWOvS9YE" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">897,323</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20240701__20240930_zXTIG3KgLZZ6" style="text-align: right" title="Net loss per common share: basic calculation">(6.96</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240701__20240930_zZiE8YoT2k68" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(3.93</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20240701__20240930_zKdtv7CWrj7d" style="text-align: right" title="Net loss per common share: diluted calculation">(6.96</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20240701__20240930_z90iYFXYzIuh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20240701__20240930_zwswZGgFUwCi" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20240701__20240930_z7WI3jrWWurh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasic_pid_c20240701__20240930_z9d2qVDlmvX" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: basic calculation">(6.96</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240701__20240930_zQyI335A6w05" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(3.93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20240701__20240930_zFyKyagTDuN6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: diluted calculation">(6.96</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the nine months ended September 30, 2024, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetLossBasicCalculation_pn3n3_c20240101__20240930_zljTz9sOdG93" style="width: 14%; text-align: right" title="Net loss, basic calculation">(9,329</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20240101__20240930_zkiISmiDNnv8" style="width: 14%; text-align: right" title="Net loss, effect of dilutive warrant securities">(3,530</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetLossDilutedCalculation_pn3n3_c20240101__20240930_zk9mbZo4LTR8" style="width: 14%; text-align: right" title="Net loss, diluted calculation">(12,859</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20240101__20240930_z3UwW2uJJsI4" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20240101__20240930_zS1Hu8l5sXN" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20240101__20240930_zPqsnVnQCcsl" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240101__20240930_zUywqBbbdrI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, basic calculation">(9,329</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeEffectOfDilutiveWarrantSecurities_pn3n3_c20240101__20240930_zZqELqHCIMz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, effect of dilutive warrant securities">(3,530</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20240101__20240930_zwfYw3GxBRzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, diluted calculation">(12,859</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zqKwn0i3khCj" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">539,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240101__20240930_zjLQP2qRjFb4" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">117,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zsLT76etl4bh" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">656,468</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20240101__20240930_zkkCrnjcDWF3" style="text-align: right" title="Net loss per common share: basic calculation">(17.30</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240101__20240930_zvfzdsVQUR5d" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(30.12</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20240101__20240930_z9QWNgkHhel5" style="text-align: right" title="Net loss per common share: diluted calculation">(19.59</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20240101__20240930_zW5XuGnmiQo" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20240101__20240930_zUL1JxsfU4fi" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20240101__20240930_zm2d0pXzNLE" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1183">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240930_z6llpr9j4Suc" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: basic calculation">(17.30</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240101__20240930_zzGASa4IKMxa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(30.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: diluted calculation">(19.59</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A8_ze880DGdy7Z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3300000 100000 <p id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkYYc1GamXP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the three months ended September 30, 2025, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zTNpTatZhh8g" style="display: none">Schedule of Basic and Diluted Loss Per Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--NetLossBasicCalculation_pn3n3_c20250701__20250930_z0dOc8GSHEE6" style="width: 14%; text-align: right" title="Net loss, basic calculation">(3,539</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20250701__20250930_zizavnvC9OO3" style="width: 14%; text-align: right" title="Net loss, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--NetLossDilutedCalculation_pn3n3_c20250701__20250930_zTYVHW9DdtTa" style="width: 14%; text-align: right" title="Net loss, diluted calculation">(3,539</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20250701__20250930_zqY1S2pR3zB" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation">(6,719</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20250701__20250930_zVC3AS9shuoi" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20250701__20250930_zbRlcY0h9hV9" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation">(6,719</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20250701__20250930_zfgo2tCsZ8yi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, basic calculation">(10,258</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--NetLossAttributableToCommonStockholdersEffectOfDilutiveWarrantSecurities_pn3n3_c20250701__20250930_zw75o7J9ZMJg" style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: right" title="Net loss attributable to common stockholders, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20250701__20250930_zC64606EWEaj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, diluted calculation">(10,258</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250701__20250930_zVE4N4yLEv62" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">2,963,539</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250701__20250930_zpXfuSGlKRF9" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">     <span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250701__20250930_zoILTkVOV2B8" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">2,963,539</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20250701__20250930_z8hw2chpjpw5" style="text-align: right" title="Net loss per common share: basic calculation">(1.19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20250701__20250930_zKoZYxi9Aq49" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20250701__20250930_zbtx9mBOidIa" style="text-align: right" title="Net loss per common share: diluted calculation">(1.19</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20250701__20250930_zE1583aM8Ghd" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation">(2.27</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20250701__20250930_zZSvRZhW7pL6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20250701__20250930_zewswi6jOYzh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation">(2.27</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasic_pid_c20250701__20250930_zjBTK6L00OQ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, basic calculation">(3.46</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetLossAttributableToCommonStockholdersEffectOfDilutiveWarrantSecurities_pid_c20250701__20250930_zstmS2dmtSSf" style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: right" title="Net loss attributable to common stockholders, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EarningsPerShareDiluted_pid_c20250701__20250930_zrF530P2lmb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, diluted calculation">(3.46</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the nine months ended September 30, 2025, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_904_ecustom--NetLossBasicCalculation_pn3n3_c20250101__20250930_zgR8iFcxYs53" title="Net loss, basic calculation">(8,149</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90F_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20250101__20250930_zHGlcQkPJzPg" title="Net loss, effect of dilutive warrant securities">(1</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90F_ecustom--NetLossDilutedCalculation_pn3n3_c20250101__20250930_zyco65PiqPQi" title="Net loss, diluted calculation">(8,150</span></td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deemed dividend related to warrant inducement</p></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Net loss, basic calculation"><span id="xdx_901_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20250101__20250930_zgcj6V0W5OQh" title="Deemed dividend related to warrant inducement, basic calculation">(6,719</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20250101__20250930_zknpTcZBvGXd" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Net loss, diluted calculation"><span id="xdx_902_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20250101__20250930_zeDsz6Q2sYp7" title="Deemed dividend related to warrant inducement, diluted calculation">(6,719</span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20250101__20250930_zbizJqOJ9odd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, basic calculation">(14,868</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeEffectOfDilutiveWarrantSecurities_pn3n3_c20250101__20250930_zj79bBt32UMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, effect of dilutive warrant securities">(1</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20250101__20250930_zsm92fomBwsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, diluted calculation">(14,869</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250930_zib7CDDArKHd" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">2,411,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20250101__20250930_zTybjCJEET7k" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250930_zNTO6p0uGROd" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">2,411,179</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20250101__20250930_z41QRbtHChtc" style="text-align: right" title="Net loss per common share: basic calculation">(3.38</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20250101__20250930_zhILUbneNH9g" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(5.71</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20250101__20250930_zsEMyeuLSOT6" style="text-align: right" title="Net loss per common share: diluted calculation">(3.38</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20250101__20250930_zOtqvv2zo9X8" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation">(2.79</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20250101__20250930_zOkOBSYcX5Aj" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20250101__20250930_z0lsXYim4Eaf" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation">(2.79</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250930_zspAWmtyIBNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: basic calculation">(6.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--NetLossAttributableToCommonStockholdersEffectOfDilutiveWarrantSecurities_pid_c20250101__20250930_z5i9M6F4jjy1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss attributable to common stockholders, effect of dilutive warrant securities">(5.71</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250930_zBGdkJyRHPYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: diluted calculation">(6.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the three months ended September 30, 2024, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--NetLossBasicCalculation_pn3n3_c20240701__20240930_z5jG49yVuSTe" style="width: 14%; text-align: right" title="Net loss, basic calculation">(6,239</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20240701__20240930_zavCTtm7HVFh" style="width: 14%; text-align: right" title="Net loss, effect of dilutive warrant securities">(4</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetLossDilutedCalculation_pn3n3_c20240701__20240930_zNVSj2t9DTf4" style="width: 14%; text-align: right" title="Net loss, diluted calculation">(6,243</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20240701__20240930_zkKUFinBwPMj" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20240701__20240930_zFfGE6N9eRDh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20240701__20240930_z719Vrc2kHb1" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240701__20240930_zjHfljbQQFoi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, basic calculation">(6,239</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--NetIncomeEffectOfDilutiveWarrantSecurities_pn3n3_c20240701__20240930_zWaCrzNW1i2g" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, effect of dilutive warrant securities">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20240701__20240930_zqP6nUJpelfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, diluted calculation">(6,243</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_z9LsTTTcKbpb" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">896,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240701__20240930_zdN9JBuA1M69" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">1,018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_zRfWOvS9YE" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">897,323</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20240701__20240930_zXTIG3KgLZZ6" style="text-align: right" title="Net loss per common share: basic calculation">(6.96</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240701__20240930_zZiE8YoT2k68" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(3.93</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20240701__20240930_zKdtv7CWrj7d" style="text-align: right" title="Net loss per common share: diluted calculation">(6.96</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20240701__20240930_z90iYFXYzIuh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20240701__20240930_zwswZGgFUwCi" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20240701__20240930_z7WI3jrWWurh" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasic_pid_c20240701__20240930_z9d2qVDlmvX" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: basic calculation">(6.96</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240701__20240930_zQyI335A6w05" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(3.93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20240701__20240930_zFyKyagTDuN6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: diluted calculation">(6.96</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are basic and diluted loss per share data for the nine months ended September 30, 2024, which are in thousands except for share and per share data:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Basic<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive<br/> Warrant<br/> Securities</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Diluted<br/> Calculation</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 46%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetLossBasicCalculation_pn3n3_c20240101__20240930_zljTz9sOdG93" style="width: 14%; text-align: right" title="Net loss, basic calculation">(9,329</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetLossEffectOfDilutiveWarrantSecurities_pn3n3_c20240101__20240930_zkiISmiDNnv8" style="width: 14%; text-align: right" title="Net loss, effect of dilutive warrant securities">(3,530</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--NetLossDilutedCalculation_pn3n3_c20240101__20240930_zk9mbZo4LTR8" style="width: 14%; text-align: right" title="Net loss, diluted calculation">(12,859</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--DeemedDividendRelatedToWarrantInducementBasicCalculation_pn3n3_c20240101__20240930_z3UwW2uJJsI4" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pn3n3_c20240101__20240930_zS1Hu8l5sXN" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--DeemedDividendRelatedToWarrantInducementDilutedCalculation_pn3n3_c20240101__20240930_zPqsnVnQCcsl" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240101__20240930_zUywqBbbdrI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, basic calculation">(9,329</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--NetIncomeEffectOfDilutiveWarrantSecurities_pn3n3_c20240101__20240930_zZqELqHCIMz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, effect of dilutive warrant securities">(3,530</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--NetIncomeLossAttributableToParentDiluted_pn3n3_c20240101__20240930_zwfYw3GxBRzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss, diluted calculation">(12,859</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zqKwn0i3khCj" style="text-align: right" title="Number of shares used in per common share calculations: basic calculation">539,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_c20240101__20240930_zjLQP2qRjFb4" style="text-align: right" title="Number of shares used in per common share calculations: effect of dilutive warrant securities">117,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zsLT76etl4bh" style="text-align: right" title="Number of shares used in per common share calculations: diluted calculation">656,468</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20240101__20240930_zkkCrnjcDWF3" style="text-align: right" title="Net loss per common share: basic calculation">(17.30</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240101__20240930_zvfzdsVQUR5d" style="text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(30.12</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20240101__20240930_z9QWNgkHhel5" style="text-align: right" title="Net loss per common share: diluted calculation">(19.59</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Deemed dividend related to warrant inducement</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--BasicDeemedDividendRelatedToWarrantInducement_pid_c20240101__20240930_zW5XuGnmiQo" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, basic calculation"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DeemedDividendRelatedToWarrantInducementEffectOfDilutiveWarrantSecurities_pid_c20240101__20240930_zUL1JxsfU4fi" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, effect of dilutive warrant securities"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--DilutedDeemedDividendRelatedToWarrantInducement_pid_c20240101__20240930_zm2d0pXzNLE" style="border-bottom: Black 1pt solid; text-align: right" title="Deemed dividend related to warrant inducement, diluted calculation"><span style="-sec-ix-hidden: xdx2ixbrl1183">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240930_z6llpr9j4Suc" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: basic calculation">(17.30</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetIncomeEffectOfDilutiveWarrantSecuritiesPerShare_pid_c20240101__20240930_zzGASa4IKMxa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: effect of dilutive warrant securities">(30.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss per common share: diluted calculation">(19.59</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -3539000 -3539000 -6719000 -6719000 -10258000 -10258000 2963539 2963539 -1.19 -1.19 -2.27 -2.27 -3.46 -3.46 -8149000 -1000 -8150000 -6719000 -6719000 -14868000 -1000 -14869000 2411004 175 2411179 -3.38 -5.71 -3.38 -2.79 -2.79 -6.17 -5.71 -6.17 -6239000 -4000 -6243000 -6239000 -4000 -6243000 896305 1018 897323 -6.96 -3.93 -6.96 -6.96 -3.93 -6.96 -9329000 -3530000 -12859000 -9329000 -3530000 -12859000 539252 117216 656468 -17.30 -30.12 -19.59 -17.30 -30.12 <p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zFZA5WBZJta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_82C_zu23pPYDspjf">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMWtbl5xKhsg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consisted of the following (in thousands):<br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_z4fS03zGGxy9" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250930_zUTP5rJJOH8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241231_zaGzFB5ksBW9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pn3n3_maINzamf_maINzhep_zlitTIg0G91f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">629</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzamf_maINzhep_zlBFrTCo3Qvk" style="vertical-align: bottom; background-color: White"> <td>WIP</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzamf_zDt8BRV1uxT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">156</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--InventoryTotal_iTI_pn3n3_mtINzamf_zZ3AZnMrCJV1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">849</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">967</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zfbehX2nZYK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, inventories of approximately $<span id="xdx_908_eus-gaap--InventoryNet_iI_pn5n6_c20250930_zoi55ITrA5a2" title="Inventory current">0.4</span> million and $<span id="xdx_90F_eus-gaap--InventoryNoncurrent_iI_pn5n6_c20250930_zoccG9SWexil" title="Inventory non-current">0.4</span> million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of September 30, 2025, that management estimates will be sold or used by September 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMWtbl5xKhsg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consisted of the following (in thousands):<br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_z4fS03zGGxy9" style="display: none">Schedule of Components of Inventory</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250930_zUTP5rJJOH8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241231_zaGzFB5ksBW9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pn3n3_maINzamf_maINzhep_zlitTIg0G91f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">478</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">629</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzamf_maINzhep_zlBFrTCo3Qvk" style="vertical-align: bottom; background-color: White"> <td>WIP</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzamf_zDt8BRV1uxT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">156</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--InventoryTotal_iTI_pn3n3_mtINzamf_zZ3AZnMrCJV1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">849</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">967</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 478000 629000 229000 182000 142000 156000 849000 967000 400000 400000 <p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zyM9EKepYnw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_823_z6cssBrcI9x">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have certain rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted market prices for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">observable prices that are based on inputs not quoted on active markets but corroborated by market data.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets or liabilities (except the derivative liabilities explained above) were measured on a recurring basis as of September 30, 2025, and December 31, 2024. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2025, and December 31, 2024 (in thousands):<br/> </span></p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z9moB0e7xkEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zln5aK3FSsq6" style="display: none">Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBqkTys3nuKf" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1213">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaSxHPTXa8u4" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVZU8xWevPN" style="width: 10%; text-align: right" title="Derivative liability">870</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zr6XTkujOXvc" style="width: 10%; text-align: right" title="Derivative liability">870</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHrjaApSmMda" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z9vJn7O7kup9" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zILe7kNp26B7" style="width: 10%; text-align: right" title="Derivative liability">208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbztH7BjkZJg" style="width: 10%; text-align: right" title="Derivative liability">208</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zTnxA0eh7cMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zoHTe4YfmYti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the nine months ended September 30, 2025, and 2024. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2025, and 2024 (in thousands):<br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zHW3vZuhOAjl" style="display: none">Schedule of Fair Value Measurement Hierarchy of Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock<br/> Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbAX33im2eJc" style="width: 16%; text-align: right" title="Beginning balance">304</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issuance of derivatives</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZo3fjS6oig5" style="text-align: right" title="Issuance of derivatives">3,366</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants_iN_pn3n3_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvbES6vucTZ3" style="text-align: right" title="Exercise of warrants">(1</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGlsH9udfGIj" style="text-align: right" title="Change in fair value">(3,459</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodOther_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKWPUe9KUJ6e" style="border-bottom: Black 1pt solid; text-align: right" title="Other">14</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkJGfWM1SRzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">224</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance as of December 31, 2024</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNLAN9lZbZ3g" style="text-align: right" title="Beginning balance">208</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Issuance of derivatives</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUAMtTM3S9u7" style="text-align: right" title="Issuance of derivatives">495</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmrjX3kNchH" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">167</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBal6pN3zxjk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zBf0Ui8yYh28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of September 30, 2025, and December 31, 2024, the derivative liability was calculated using the Monte Carlo simulation valuation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zjHOf5fv8A75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumptions used in estimating the common stock warrant liability using the Monte Carlo simulation valuation model as of September 30, 2025, and December 31, 2024 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zTEMd9Hm2cz2" style="display: none">Schedule of Assumptions Used in Estimating Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, <br/> 2025 </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, <br/> 2024 </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zMlM5PvEq7Q7" title="Weighted-average expected volatility">3.57</span>-<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zeW71Iu0xgD1" title="Weighted-average expected volatility">3.69</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zs1OnRNKpc94" title="Weighted-average expected volatility">4.12</span>-<span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zmzXhPwatU47" title="Weighted-average expected volatility">4.35</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zWwueyOtrA2a" title="Weighted-average expected life">0.05</span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z9W9Og8Potdd" title="Weighted-average expected life">4.75</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zvJASwH2KSLj" title="Weighted-average expected life">0.10</span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zjit5VGWaX84" title="Weighted-average expected life">4.09</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdyXT8Rtjey3" style="text-align: right" title="Weighted-average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zD8AyCZde8be" style="text-align: right" title="Weighted-average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zeLri5aqRVO8" title="Warrants measurement input">135.00</span>-<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zbln1cF28m6g" title="Warrants measurement input">170.00</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zOLLWK2D4gAb" title="Warrants measurement input">140.00</span>-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zqW0H2qPVSE6" title="Warrants measurement input">210.00</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A6_znpTxGeju2gi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Financial Instruments</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s recorded values of cash and cash equivalents, account and other receivables, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z9moB0e7xkEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zln5aK3FSsq6" style="display: none">Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBqkTys3nuKf" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1213">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zaSxHPTXa8u4" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVZU8xWevPN" style="width: 10%; text-align: right" title="Derivative liability">870</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20250930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zr6XTkujOXvc" style="width: 10%; text-align: right" title="Derivative liability">870</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zHrjaApSmMda" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z9vJn7O7kup9" style="width: 10%; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zILe7kNp26B7" style="width: 10%; text-align: right" title="Derivative liability">208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbztH7BjkZJg" style="width: 10%; text-align: right" title="Derivative liability">208</td><td style="width: 1%; text-align: left"> </td></tr> </table> 870000 870000 208000 208000 <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zoHTe4YfmYti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the nine months ended September 30, 2025, and 2024. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2025, and 2024 (in thousands):<br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zHW3vZuhOAjl" style="display: none">Schedule of Fair Value Measurement Hierarchy of Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock<br/> Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbAX33im2eJc" style="width: 16%; text-align: right" title="Beginning balance">304</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issuance of derivatives</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZo3fjS6oig5" style="text-align: right" title="Issuance of derivatives">3,366</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants_iN_pn3n3_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvbES6vucTZ3" style="text-align: right" title="Exercise of warrants">(1</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGlsH9udfGIj" style="text-align: right" title="Change in fair value">(3,459</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodOther_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKWPUe9KUJ6e" style="border-bottom: Black 1pt solid; text-align: right" title="Other">14</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkJGfWM1SRzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">224</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance as of December 31, 2024</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNLAN9lZbZ3g" style="text-align: right" title="Beginning balance">208</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Issuance of derivatives</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUAMtTM3S9u7" style="text-align: right" title="Issuance of derivatives">495</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmrjX3kNchH" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">167</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBal6pN3zxjk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 304000 3366000 1000 -3459000 14000 224000 208000 495000 167000 870000 <p id="xdx_895_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zjHOf5fv8A75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumptions used in estimating the common stock warrant liability using the Monte Carlo simulation valuation model as of September 30, 2025, and December 31, 2024 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zTEMd9Hm2cz2" style="display: none">Schedule of Assumptions Used in Estimating Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, <br/> 2025 </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, <br/> 2024 </b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zMlM5PvEq7Q7" title="Weighted-average expected volatility">3.57</span>-<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zeW71Iu0xgD1" title="Weighted-average expected volatility">3.69</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zs1OnRNKpc94" title="Weighted-average expected volatility">4.12</span>-<span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zmzXhPwatU47" title="Weighted-average expected volatility">4.35</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zWwueyOtrA2a" title="Weighted-average expected life">0.05</span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z9W9Og8Potdd" title="Weighted-average expected life">4.75</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zvJASwH2KSLj" title="Weighted-average expected life">0.10</span>-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zjit5VGWaX84" title="Weighted-average expected life">4.09</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdyXT8Rtjey3" style="text-align: right" title="Weighted-average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zD8AyCZde8be" style="text-align: right" title="Weighted-average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zeLri5aqRVO8" title="Warrants measurement input">135.00</span>-<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zbln1cF28m6g" title="Warrants measurement input">170.00</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zOLLWK2D4gAb" title="Warrants measurement input">140.00</span>-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByLiabilityClassAxis__custom--CommonStockWarrantsMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMertonValuationModelMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zqW0H2qPVSE6" title="Warrants measurement input">210.00</span></span></td><td style="text-align: left">%</td></tr> </table> 3.57 3.69 4.12 4.35 P0Y18D P4Y9M P0Y1M6D P4Y1M2D 135.00 170.00 140.00 210.00 <p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zIZFeKFppETi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_82A_zEy0dmZhEfgd">Accrued and Other Current Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zjAPugcrzy29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zDtnjjGYJzfb" style="display: none">Schedule of Accrued and Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250930_zUs0q4NVeXI1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_z9yE089oioU3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzlGL_maALCzIcn_ztZop7eEIZsh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">494</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">400</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccruedPayableCurrent_iI_pn3n3_maALCzlGL_maALCzIcn_znMAf9oeWMje" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzlGL_maALCzIcn_zRd8CJSEIQIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">453</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">408</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzIcn_zu6gqoDufT0e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued other liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zb5I2wxbgRMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current liabilities consisted of deposits for stock issuance of $<span id="xdx_90B_eus-gaap--Deposits_iI_pn5n6_c20250930_zXKzGkk8qEea" title="Deposit for stock issuance">1.8</span> million. The stock issuance is related to the 2025 Warrant Inducement (see Note 9), and the stock is held in abeyance, as of September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zjAPugcrzy29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zDtnjjGYJzfb" style="display: none">Schedule of Accrued and Other Current Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250930_zUs0q4NVeXI1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_z9yE089oioU3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzlGL_maALCzIcn_ztZop7eEIZsh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">494</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">400</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccruedPayableCurrent_iI_pn3n3_maALCzlGL_maALCzIcn_znMAf9oeWMje" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzlGL_maALCzIcn_zRd8CJSEIQIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">453</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">408</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzIcn_zu6gqoDufT0e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued other liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 494000 400000 103000 178000 453000 408000 1050000 986000 1800000 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zbDpT6y9kHV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_828_zX30CHokxfj3">Debt</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Insurance Premium Finance Arrangements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2024, in connection with securing commercial liability insurance, the Company entered into a Premium Finance Arrangement to extend the premium payment out for a period of 10 months. The Company paid a total of $<span id="xdx_90F_ecustom--UpFrontInsurancePremium_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember_zPjZsVmi2OS1" title="Up front insurance premium">26,000</span> up front toward the insurance premium and financed approximately $<span id="xdx_90E_ecustom--FinancedInsurancePremium_c20240601__20240630__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember_zTK4YdSHr3a9" title="Financed insurance premium">117,000</span>. The Company made 10 equal payments under the terms of the Premium Finance Agreement. The Premium Finance Agreement bears interest at an annual percentage rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240630__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember_z2DOL0fOH6ai" title="Debt interest rate">8.75</span>%. The loan was paid in full during the first quarter of 2025 and there was<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_do_c20250930__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember_z2MV7R0jjt79" title="Outstanding balance"> no</span> outstanding balance as of September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2025, in connection with securing Director and Officer professional liability insurance, the Company entered into a Premium Finance Arrangement to extend the premium payment out for a period of 10 months. The Company paid a total of $<span id="xdx_909_ecustom--UpFrontInsurancePremium_c20250301__20250331__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zYtPpTSsUCT7" title="Up front insurance premium">26,000</span> up front toward the insurance premium and financed approximately $<span id="xdx_90D_ecustom--FinancedInsurancePremium_c20250301__20250331__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zkLwbsXjq0I3" title="Financed insurance premium">145,000</span>. The Company will make 10 equal payments under the terms of the Premium Finance Agreement. The Premium Finance Agreement bears interest at an annual percentage rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250331__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zSnJTyRWptGg" title="Debt interest rate">7.45</span>%. The outstanding balance totaled $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zT0g27ocJgUj" title="Outstanding balance">45,000</span> as of September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2025, in connection with securing general liability insurance, the Company entered into a Premium Finance Arrangement to extend the premium payment out for a period of 5 months. The Company paid a total of $<span id="xdx_904_eus-gaap--PaymentsForUnderwritingExpense_c20250501__20250531__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zmIA3b0kybf3" title="Payment of insurance premium">14,000</span> up front toward the insurance premium and financed approximately $<span id="xdx_90C_eus-gaap--PaymentsToAcquireFinanceReceivables_c20250501__20250531__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zPcr21LLnhJf" title="Payments to financed total">21,000</span>. The Company will make 3 equal payments under the terms of the Premium Finance Agreement. The Premium Finance Agreement bears interest at an annual percentage rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250930__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_z31Fpl3rYP54" title="Annual interest rate">11.15</span>%. The outstanding balance totaled $<span id="xdx_903_eus-gaap--ShorttermDebtAverageOutstandingAmount_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--InsurancePremiumFinanceArrangementsMember__srt--ProductOrServiceAxis__custom--DirectorAndOfficerProfessionalLiabilityInsuranceMember_zg1RqebysYwl" title="Outstanding balance">14,000</span> as of September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 26000 117000 0.0875 26000 145000 0.0745 45000 14000 21000 0.1115 14000 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zYAd7i5vOyvd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_82F_zoyE5stnaTg9">Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2025 Warrant Inducement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2025, the Company entered into an inducement agreement (the “Inducement Letter”) with certain holders of certain of the Company’s existing warrants to purchase up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250225__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zcFIoirtQC17" title="Warrants purchase, shares">1,099,431</span> shares of the Company’s common stock originally issued on February 25, 2025, with a five and one-half (<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250225__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zhP7EfzDOjK6" title="Warrants term">5.5</span>) years term at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250225__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zIRk1h4L8V1g" title="Exercise price">3.32</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Inducement Letter, the warrant holders agreed to exercise for cash the existing warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250225__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zM7dhlnzWAka" title="Warrants purchase, shares">1,099,431</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250225__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zGCn0W2H5g49" title="Exercise price">3.32</span> per share in consideration of the Company’s agreement to issue new common stock purchase warrants to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250908__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zRLbQq716wJ2" title="Warrants purchase, shares">1,649,147</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250908__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_z0PNmkhXcbr" title="Exercise price">4.79</span> per share. In addition, the warrant holders agreed to pay $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20250908__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_zj2GoCPfyam2" title="Share price">0.125</span> per new warrant as consideration for the issuance of the new warrants. The Company received aggregate gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250908__20250908__us-gaap--TypeOfArrangementAxis__custom--InducementLetterMember_z1VkwhLJK3s8" title="gross proceeds from exercise warrant">3.8 </span>million from the exercise of the existing warrants by the warrant holder, before deducting placement agent fees and other offering expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company estimated the fair value of each warrant on the issuance date using the Black-Scholes-Merton valuation model. The aggregate fair value of the new warrants issued as part of the inducement was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20250908__20250908_zim010WKr98j" title="Fair value of new warrants issued as part of the inducement">6.7</span> million, which is presented as a deemed dividend on the condensed consolidated statements of operations and the condensed consolidated statements of stockholders’ equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2025 Capital Raise and registration of shares</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 20, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) under which it sold securities to certain institutional and accredited investors for aggregate gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20250220__20250220_z6qPQnadKxZd">5.0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting fees to the placement agent and other expenses payable by the Company in connection with the private placement. As part of the Private Placement, the Company issued (i) <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20250220_zuBnZGFWRc25">1,171,189</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock, (ii) pre-funded warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250220__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zEHwCWqixm7d">278,098</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the “Pre-Funded Warrants”) with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250220__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zfAWGc3fDDLl">0.0001</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, and (iii) warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250220__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuZm9UcsGDJh">1,449,287</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock (the “Common Warrants”) with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250220__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztqbITTpYuWh">3.32</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The purchase price per share of common stock and the associated Common Warrant was $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250220__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGy49ZHhFYLh">3.45</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the purchase price per Pre-Funded Warrant and associated Common Warrant was $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250220__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zGJf3nyxB2mf">3.4499</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Common Warrants are exercisable immediately and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20250220__20250220__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbPI1orxLQuf">expire five-and one-half years from issuance</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Pre-Funded Warrants are exercisable immediately and terminate when exercised in full. The Company filed a Registration Statement on Form S-3 registering the resale of the above-mentioned Securities, which was declared effective by the SEC on March 27, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024 April Registered Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2024, the Company closed a public offering of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240405__20240405__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourAprilRegisteredOfferingMember_ztHaXKL0EYV2" title="Number of shares issued">358,000</span> shares of the Company’s common stock, (the “Offering”). Each Share was sold at a public offering price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20240405__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourAprilRegisteredOfferingMember_znuhqkhfPBYe" title="Public offering price">4.20</span>. The aggregate proceeds to the Company from the Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240405__20240405__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourAprilRegisteredOfferingMember_zyIAY642oQA8" title="Proceeds from issuance of common stock">1.5</span> million before deducting placement agent fees and other estimated offering expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024 March Registered Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 26, 2024, the Company closed a public offering of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240326__20240326__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourMarchRegisteredOfferingMember_zsZYFN5ilYVi" title="Number of shares issued">142,000</span> shares of the Company’s common stock, (the “Offering”). Each Share was sold at a public offering price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20240326__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourMarchRegisteredOfferingMember_zUj1AjzBL8ki" title="Public offering price">9.40</span>. The aggregate proceeds to the Company from the Offering were approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240326__20240326__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourMarchRegisteredOfferingMember_zp73mJlgRgMl" title="Proceeds from issuance of common stock">1.3</span> million before deducting placement agent fees and other estimated offering expenses payable by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024 February Registered Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 2, 2024, the Company completed a public offering of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zOxuSkT637Rj" title="Number of shares issued">80,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">units, resulting in gross proceeds of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zCVYuZeZKVN" title="Number of shares issued, value">4.0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million before deducting placement agent fees and offering expenses payable by the Company. Each unit consisted of either (i) one share of the Company’s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zQvwSBTLh11a" title="Common stock, par value">0.01</span> per share (“Common Stock”), or (ii) one pre-funded warrant to purchase one share of Common Stock, together with one Class E warrant and one Class F warrant to purchase additional shares of Common Stock. The offering included <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonUnitsMember_zThha1uobzfj" title="Number of shares issued">17,000</span> units containing shares of Common Stock (the “Common Units”) and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantUnitsMember_zxFSuqNfcaT9" title="Number of shares issued">63,000</span> units containing pre-funded warrants (the “Pre-Funded Warrant Units”). The Common Units were sold at a public offering price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonUnitsMember_z1zLRZK3lpk2">50.00</span></span> per unit, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the Pre-Funded Warrant Units were sold at a public offering price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantUnitsMember_z0EW1jmIvEUg">49.98</span> per unit. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each pre-funded warrant is exercisable for one share of Common Stock at an exercise price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_za8IP1D7Cb11">0.0001</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and is exercisable immediately, subject to a beneficial ownership limitation of <span id="xdx_908_ecustom--BeneficialOwnershipLimitationPercentage_pid_dp_uPure_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zQyO96BxB2P7" title="Beneficial ownership limitation">4.99</span>% or 9.99%. The Class E and Class F warrants are also exercisable immediately, subject to the same ownership limitation, at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassEWarrantsMember_zuuKwz6qgvX7" title="Exercise price of warrants"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassFWarrantsMember_ziIEyWdgfZxl" title="Exercise price of warrants">50.00</span></span> per share. The Class E warrants expire <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassEWarrantsMember_zZgni4CpJrF2">five years</span> after issuance, and the Class F warrants expire <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassFWarrantsMember_znpP3PqPRrdd">18</span> months after issuance. Maxim Group LLC acted as the sole placement agent for the offering. Pursuant to the placement agency agreement, the Company paid a cash placement fee equal to <span id="xdx_906_ecustom--PercentageOfCashPlacementFee_pid_dp_uPure_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zUu9E9pA9qUl" title="Placement fee percentage">7.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the gross proceeds, plus reimbursement of expenses and legal fees up to $<span id="xdx_903_ecustom--ReimbursementOfExpensesAndLegalFees_pp0p0_c20240202__20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zDnReEsjyqe2" title="Reimbursement of expenses and legal fees">100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company also issued to the placement agent up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__srt--RangeAxis__srt--MaximumMember_zRFOpxfxJ8wf">3,200</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase shares of Common Stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zQ6HKhFbyMVh" title="Exercise price of warrants">55.00</span> per share. These placement agent warrants become exercisable on July 31, 2024, and expire <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240202__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourFebruaryRegisteredOfferingMember_zyZCJRqsp7Le">five years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">after the commencement of sales in the offering. Proceeds from the offering were used for general corporate purposes, including working capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021 Equity Distribution Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 ATM Agreement”) with Maxim Group LLC (the “Agent”) as sales agent. The agreement permitted the Company to offer and sell shares of its common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210225__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zTFJYboHTjCh">0.01</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (“Common Stock”), from time to time in an “at-the-market” offering for an aggregate offering amount of up to $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20210225__20210225__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__dei--LegalEntityAxis__custom--MaximGroupLLCMember__srt--RangeAxis__srt--MaximumMember_zqiwAbMlOLD2" title="Offering Amount">15.0</span> million, as amended on January 10, 2023 and October 12, 2023. On March 22, 2024, the Company suspended sales under the 2021 ATM Agreement and terminated the continuous offering. On July 11, 2024, the Company filed a Prospectus Supplement with the Securities and Exchange Commission adjusting the remaining capacity under the 2021 ATM Agreement to approximately $<span id="xdx_90B_eus-gaap--ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_pn5n6_c20240711__20240711__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zYUzPKpAa4Og">3.1</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and subsequently resumed sales of Common Stock under the program. During the year ended December 31, 2024, the Company sold an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zQGGlO118vn8">602,357</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Common Stock pursuant to the 2021 ATM Agreement, resulting in gross proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOneEquityDistributionAgreementMember__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zlGQnRHGw256" title="Gross proceeds">3.7</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million before deducting sales commissions and offering expenses. The 2021 ATM Agreement terminated in accordance with its terms on February 25, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1099431 P5Y6M 3.32 1099431 3.32 1649147 4.79 0.125 3800000 6700000 5000000.0 1171189 278098 0.0001 1449287 3.32 3.45 3.4499 expire five-and one-half years from issuance 358000 4.20 1500000 142000 9.40 1300000 80000 4000000.0 0.01 17000 63000 50.00 49.98 0.0001 0.0499 50.00 50.00 P5Y P18M 0.070 100000 3200 55.00 P5Y 0.01 15000000.0 3100000 602357 3700000 <p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zImUcwEDED0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_820_zH9b8q6XKGW5">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zliytkwPTjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s outstanding stock option activity for the nine months ended September 30, 2025, and 2024 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zqC0cKtauG57" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">As of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_z540n0roTnyl" style="width: 10%; text-align: right" title="Options outstanding at beginning">35</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_z4QEDYtprZS3" style="width: 10%; text-align: right" title="Weighted average exercisable price">18,872</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z6MSBhtAyxrb" title="Weighted average remaining contractual terms (years), outstanding">5.5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20250101__20250930_zMAbKhLjvV4a" style="width: 10%; text-align: right" title="Intrinsic value, outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1414">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z1FgGsMMDxv9" style="text-align: right" title="Options, granted">170,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zKJhCbZaCw2d" style="text-align: right" title="Weighted average exercise price, granted">3.65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantedRemainingContractualTerm2_dtY_c20250101__20250930_zt8DLQyPZjje" title="Weighted average remaining contractual terms (years), outstanding Granted">9.7</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20250930_zR48LHltASZg" style="text-align: right" title="Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1422">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930_z1r92lWkxpu2" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1424">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930_zcUuNjc8dzr" style="text-align: right" title="Options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzOTDrhMcI08" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zgQhyKYPUu5k" style="border-bottom: Black 1pt solid; text-align: right" title="Options, expired">(3</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zTZexM3U59o1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">19,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">As of September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zMcpXrn5p3X5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, outstanding at end">170,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zdjmHCkcATX9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at end of period">8.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zFEvHzbLockj" title="Weighted average remaining contractual terms (years), outstanding">9.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20250101__20250930_zWiEJ3pTTe3c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding at end of period">98,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20250930_zdsQ1PdVSdX7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, exercisable at end">170,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zhk8hAbArxGc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable at end of period">8.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zEJvsesdpUB2" title="Weighted average remaining contractual terms (years), exercisable">9.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20250101__20250930_zsaY3BDUK7ql" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable at end of period">98,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20250930_zzQoQzLQDuza" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and expected to vest at end">170,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zH9OhpKFWM" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest at end">8.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zuTIJfVvOBZ3" title="Weighted average remaining contractual terms (years), vested and expected to vest">9.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20250101__20250930_zEodWZTudAW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest end of period">98,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">As of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zzKXHqAfhp63" style="width: 10%; text-align: right" title="Options outstanding at beginning">60</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zqkAz0Q4Nx9f" style="width: 10%; text-align: right" title="Weighted average exercisable price">21,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z6xi1HVLGUlh" title="Weighted average remaining contractual terms (years), outstanding">6.9</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_zQcbYmC4xakb" style="width: 10%; text-align: right" title="Intrinsic value, outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930_zcy59zNaH6O2" style="text-align: right" title="Options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1466">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zNhhvz25MYRf" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240930_zTqId8Q7i9mc" style="text-align: right" title="Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zdA45KoN2uT3" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zMPNH7xYsfH3" style="text-align: right" title="Options, forfeited">(13</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zlinqg9a1Tff" style="text-align: right" title="Weighted average exercise price, forfeited">26,749</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930_ze9UpFpNU4zg" style="border-bottom: Black 1pt solid; text-align: right" title="Options, expired">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zBOLajTCROT9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">891,768,343</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">As of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_zm47cnxZjHu3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, outstanding at end">46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zwkwQgAOCWk6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at end of period">19,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zlMG0xc1awQd" title="Weighted average remaining contractual terms (years), outstanding">5.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_ziUnr0ucIQn2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_zOjZ1wBAMr08" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, exercisable at end">45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zIQZNkqVaeFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable at end of period">26,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zgCi9NZZVNq5" title="Weighted average remaining contractual terms (years), exercisable">6.3</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zXWNal5vlcv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1496">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930_z58lKPj1ymbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and expected to vest at end">22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zw3n1bPd4iGf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest at end">29,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zFBqUGE2An53" title="Weighted average remaining contractual terms (years), vested and expected to vest">5.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930_zeuOhFK0drjj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest end of period"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zMFIu4CLJ7te" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of the Company. The expected term was contractual life of option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsY4hDGCht3k" title="Options outstanding">170,032</span> options outstanding as of September 30, 2025, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__srt--TitleOfIndividualAxis__custom--NonExecutiveMember_zTo7yuKgaWL5" title="Options, grants in period, gross">170,018</span> were awarded to non-executive members of the board of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zeVanoIaXT3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrecognized stock-based compensation as of September 30, 2025, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_z0PJHUqDkFwi" style="display: none">Schedule of Unrecognized Stock-based Compensation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrecognized</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Stock-Based<br/> Compensation</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognition</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock options</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockOptionMember_zWLdxQKAwyic" style="text-align: right" title="Unrecognized stock-based compensation"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Stock grants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeStockGrantsMember_zgIL4cOxeFrb" style="width: 16%; text-align: right" title="Unrecognized stock-based compensation">2,081</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeStockGrantsMember_zdRgGJoEMQB2" title="Weighted average remaining of recognition">1.3</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zjlKOlKj6qPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zliytkwPTjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s outstanding stock option activity for the nine months ended September 30, 2025, and 2024 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zqC0cKtauG57" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">As of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_z540n0roTnyl" style="width: 10%; text-align: right" title="Options outstanding at beginning">35</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_z4QEDYtprZS3" style="width: 10%; text-align: right" title="Weighted average exercisable price">18,872</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_z6MSBhtAyxrb" title="Weighted average remaining contractual terms (years), outstanding">5.5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20250101__20250930_zMAbKhLjvV4a" style="width: 10%; text-align: right" title="Intrinsic value, outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1414">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z1FgGsMMDxv9" style="text-align: right" title="Options, granted">170,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zKJhCbZaCw2d" style="text-align: right" title="Weighted average exercise price, granted">3.65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantedRemainingContractualTerm2_dtY_c20250101__20250930_zt8DLQyPZjje" title="Weighted average remaining contractual terms (years), outstanding Granted">9.7</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20250101__20250930_zR48LHltASZg" style="text-align: right" title="Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1422">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930_z1r92lWkxpu2" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1424">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930_zcUuNjc8dzr" style="text-align: right" title="Options, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzOTDrhMcI08" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930_zgQhyKYPUu5k" style="border-bottom: Black 1pt solid; text-align: right" title="Options, expired">(3</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zTZexM3U59o1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">19,267</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">As of September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zMcpXrn5p3X5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, outstanding at end">170,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zdjmHCkcATX9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at end of period">8.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_zFEvHzbLockj" title="Weighted average remaining contractual terms (years), outstanding">9.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20250101__20250930_zWiEJ3pTTe3c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding at end of period">98,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20250930_zdsQ1PdVSdX7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, exercisable at end">170,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zhk8hAbArxGc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable at end of period">8.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zEJvsesdpUB2" title="Weighted average remaining contractual terms (years), exercisable">9.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20250101__20250930_zsaY3BDUK7ql" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable at end of period">98,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20250101__20250930_zzQoQzLQDuza" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and expected to vest at end">170,032</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zH9OhpKFWM" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest at end">8.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zuTIJfVvOBZ3" title="Weighted average remaining contractual terms (years), vested and expected to vest">9.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20250101__20250930_zEodWZTudAW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest end of period">98,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p></td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">As of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zzKXHqAfhp63" style="width: 10%; text-align: right" title="Options outstanding at beginning">60</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zqkAz0Q4Nx9f" style="width: 10%; text-align: right" title="Weighted average exercisable price">21,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z6xi1HVLGUlh" title="Weighted average remaining contractual terms (years), outstanding">6.9</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_zQcbYmC4xakb" style="width: 10%; text-align: right" title="Intrinsic value, outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930_zcy59zNaH6O2" style="text-align: right" title="Options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1466">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zNhhvz25MYRf" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240930_zTqId8Q7i9mc" style="text-align: right" title="Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zdA45KoN2uT3" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zMPNH7xYsfH3" style="text-align: right" title="Options, forfeited">(13</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zlinqg9a1Tff" style="text-align: right" title="Weighted average exercise price, forfeited">26,749</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930_ze9UpFpNU4zg" style="border-bottom: Black 1pt solid; text-align: right" title="Options, expired">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zBOLajTCROT9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, expired">891,768,343</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">As of September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_zm47cnxZjHu3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, outstanding at end">46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zwkwQgAOCWk6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding at end of period">19,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zlMG0xc1awQd" title="Weighted average remaining contractual terms (years), outstanding">5.9</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_ziUnr0ucIQn2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_zOjZ1wBAMr08" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, exercisable at end">45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zIQZNkqVaeFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable at end of period">26,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zgCi9NZZVNq5" title="Weighted average remaining contractual terms (years), exercisable">6.3</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zXWNal5vlcv6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable at end of period"><span style="-sec-ix-hidden: xdx2ixbrl1496">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930_z58lKPj1ymbi" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and expected to vest at end">22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zw3n1bPd4iGf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest at end">29,359</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zFBqUGE2An53" title="Weighted average remaining contractual terms (years), vested and expected to vest">5.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930_zeuOhFK0drjj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest end of period"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 35 18872 P5Y6M 170000 3.65 P9Y8M12D 3 19267 170032 8.70 P9Y8M12D 98300 170032 8.70 P9Y8M12D 98300 170032 8.70 P9Y8M12D 98300 60 21954 P6Y10M24D 13 26749 1 891768343 46 19969 P5Y10M24D 45 26105 P6Y3M18D 22 29359 P5Y9M18D 170032 170018 <p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zeVanoIaXT3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrecognized stock-based compensation as of September 30, 2025, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_z0PJHUqDkFwi" style="display: none">Schedule of Unrecognized Stock-based Compensation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrecognized</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Stock-Based<br/> Compensation</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recognition</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Stock options</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockOptionMember_zWLdxQKAwyic" style="text-align: right" title="Unrecognized stock-based compensation"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Stock grants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeStockGrantsMember_zgIL4cOxeFrb" style="width: 16%; text-align: right" title="Unrecognized stock-based compensation">2,081</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--EmployeeStockGrantsMember_zdRgGJoEMQB2" title="Weighted average remaining of recognition">1.3</span></td><td style="width: 1%; text-align: left"> </td></tr> </table> 2081000 P1Y3M18D <p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znw7lbDwyGn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_821_zBPyl5EEuJ11">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zG05fzWuQ8C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_829_z1ErO0MydcTc">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into multiple operating leases from which it conducts its business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SINTX</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases <span id="xdx_905_eus-gaap--AreaOfLand_iI_usqft_c20250930_zdGcg1BLCrM9" title="Area of land">30,764</span> square feet of office, warehouse and manufacturing space under a single operating lease. <span id="xdx_909_eus-gaap--LesseeOperatingLeaseDescription_c20250101__20250930_zUALNnBu9oFb" title="Lease expires">This lease expires in October 2031</span>. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20250101__20250930_zP2G8NqFONHl" title="Lease term extend">The lease has one five-year extension option</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SINTX Armor</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, on behalf of SINTX Armor, leases approximately <span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20250930__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember_zLk3C4AnABK3">10,936</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">square feet of office and manufacturing space from which SINTX Armor conducted its operations. <span id="xdx_902_eus-gaap--LesseeOperatingLeaseDescription_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember_zWSUsIVIkm07" title="Lease expires">This lease expires in October 2031</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Impairment of operating lease right-of-use assets of $<span id="xdx_906_eus-gaap--OperatingLeaseImpairmentLoss_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember_z6XjfX8RdZc2">0.7</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million was recorded during 2024 related to Armor exit costs. In October 2025, the Company entered into a sublease agreement for the full <span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20251031__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zG5wZEn6sZK1" title="Area of land">10,936</span> square foot space, which also expires in October 2031 (totaling approximately $<span id="xdx_908_eus-gaap--LeaseCost_c20251001__20251031__us-gaap--TypeOfArrangementAxis__custom--ArmorFacilityMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoPXYPZKf146" title="Lease cost">950,000</span> over the sublease term). The sublease agreement is effective November 1, 2025, and is subject to landlord approval. A more detailed discussion of the new sublease agreement is set forth in Note 14. Subsequent Events, below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TA&amp;T</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the disposition of TA&amp;T, the lease facilities, including right of use assets and lease liabilities, were transferred to Tethon (see Note 2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, operating lease right-of-use assets were approximately $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn5n6_c20250930_zCwGPfmCFWD8" title="Operating lease right-of-use assets">2.5</span> million, and operating lease liability was approximately $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pn5n6_c20250930_zGRKi4Pyf6w3" title="Operating lease liability">3.3</span> million. Non-cash operating lease expense was immaterial during the nine months ended September 30, 2025 and 2024. As of September 30, 2025, the weighted-average discount rate for the Company’s operating lease was <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20250930_zn303UKytdJ7" title="Operating lease, weighted average discount rate, percent">8.8</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zP1yjnO2usri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease future minimum payments together with the present values as of September 30, 2025, are summarized as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zDSB7pabcnqh" style="display: none">Schedule of Operating Lease Future Minimum Payments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250930_zGHXd2zm5Fhb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzCkL_zjgXjN1auXVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2025 (Remainder)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">165</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzCkL_zqcJsYjLXq36" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">668</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzCkL_ztZIJHWRmOab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzCkL_zSlEYC3l4VP5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">709</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzCkL_zkqpqsgzg2Sf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">730</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPzCkL_zSeonR6iBW6l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,395</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzCkL_z4OC4QPMLML8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,355</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpA1epSTlRWe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less amounts representing interests</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,022</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zwEunsSe1AR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Present value of lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,333</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_zpjWdFrocd2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Current portion of operating lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">384</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zO2VVgtVowW9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Long-term portion operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,949</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zqqOYjvl36Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 30764 This lease expires in October 2031 The lease has one five-year extension option 10936 This lease expires in October 2031 700000 10936 950000 2500000 3300000 0.088 <p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zP1yjnO2usri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease future minimum payments together with the present values as of September 30, 2025, are summarized as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zDSB7pabcnqh" style="display: none">Schedule of Operating Lease Future Minimum Payments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250930_zGHXd2zm5Fhb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzCkL_zjgXjN1auXVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2025 (Remainder)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">165</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzCkL_zqcJsYjLXq36" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">668</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzCkL_ztZIJHWRmOab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzCkL_zSlEYC3l4VP5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">709</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzCkL_zkqpqsgzg2Sf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">730</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPzCkL_zSeonR6iBW6l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,395</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzCkL_z4OC4QPMLML8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,355</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpA1epSTlRWe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less amounts representing interests</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,022</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zwEunsSe1AR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Present value of lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,333</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_zpjWdFrocd2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Current portion of operating lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">384</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zO2VVgtVowW9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Long-term portion operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,949</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 165000 668000 688000 709000 730000 1395000 4355000 1022000 3333000 384000 2949000 <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zKh5Z0wV9DLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_82D_zJPSjTHZF7dh">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2025, the Company entered into a Research Collaboration Agreement (“Research Agreement”) with a company that is majority owned by a shareholder of the Company. The Company paid $<span id="xdx_902_ecustom--PaymentOfResearchFund_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--ResearchCollaborationAgreementMember_zLgNcwKgnD3j" title="Payment of research fund">500,000</span> to fund the Research Agreement. As of September 30, 2025, the remaining prepaid balance was $<span id="xdx_90F_ecustom--ResearchFundRemainingPrepaidBalance_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--ResearchCollaborationAgreementMember__us-gaap--BalanceSheetLocationAxis__us-gaap--PrepaidExpensesAndOtherCurrentAssetsMember_zEldDbFZlKqa" title="Research fund remaining prepaid balance">6,000</span>, included in prepaid expenses and other current assets on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000 6000 <p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_znWkMUVjVzz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. <span id="xdx_82A_zLwZ0nYVpfI2">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Wainwright ATM</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2025, the Company entered into an At The Market Offering Agreement (the “2025 ATM Agreement”) with H.C. Wainwright &amp; Co., LLC, as sales agent (“Wainwright”), to sell shares of its common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251003__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zw82cifR4BEk" title="Common stock, par value">0.01</span> per share (the “2025 ATM Shares”) from time to time, through an “at the market offering” program under which Wainwright will act as sales agent. The sales, if any, of the 2025 ATM Shares made under the 2025 ATM Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company’s common stock. The 2025 ATM Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-274951) initially filed by the Company with the SEC on October 12, 2023, and declared effective by the SEC on November 27, 2023, and related prospectus supplements to be prepared and filed pursuant to Rule 424(b) from time to time in connection with the offer and sale of the Shares. A prospectus supplement, dated October 3, 2025, covering the offer and sale of the 2025 ATM Shares having an aggregate offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20251003__20251003__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIa67X5r2a3c" title="Offering price">6,413,876</span> was filed with the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sublease Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 30, 2025, the Company entered into a Sublease Agreement (the “Sublease”) with Hayes Performance Systems, Inc., a Delaware corporation (“Hayes”), pursuant to which the Company agreed to sublease to Hayes all of the premises the Company currently leases under its Industrial Lease Agreement dated August 19, 2021 with SLS Industrial Portfolio Owner SLCP, LLC (the “Prime Lease”). The <span id="xdx_900_eus-gaap--LesseeOperatingLeaseDescription_c20251030__20251030__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjTRUflfgLO6" title="Term of agreement">Sublease term commences on November 1, 2025, and expires on October 31, 2031</span>, unless earlier terminated in accordance with the Sublease or upon termination of the Prime Lease. Under the Sublease, Hayes will pay the Company base rent ranging from approximately $<span id="xdx_903_eus-gaap--PaymentsForRent_c20251030__20251030__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zLV2n3vaZpRk" title="Monthly base rent">9,700</span> per month during the first year of the Sublease to approximately $<span id="xdx_907_eus-gaap--PaymentsForRent_c20251030__20251030__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zwwtDDwmCZre" title="Monthly base rent">11,300</span> per month during the final year of the term, plus its proportionate share of operating expenses and taxes, currently estimated at $<span id="xdx_907_ecustom--RentableArea_iI_c20251030__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwCfwtJefLa3" title="Rentable square foot per month">0.25</span> per rentable square foot per month. The Sublease provides for a three-month rent deferral totaling approximately $<span id="xdx_908_eus-gaap--DeferredRentReceivablesNet_iI_c20251030__us-gaap--TypeOfArrangementAxis__custom--SubleaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwoK6JkumM1" title="Deferred rent">29,200</span>, which will be repaid in six equal monthly installments beginning February 1, 2026. The Sublease is structured as a triple-net arrangement under which Hayes will be responsible for substantially all costs associated with the Subleased Premises, including utilities, maintenance, and insurance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.01 6413876 Sublease term commences on November 1, 2025, and expires on October 31, 2031 9700 11300 0.25 29200